Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Rheumatology (Oxford) ; 63(3): 787-790, 2024 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-37540112

RESUMO

OBJECTIVE: Monoclonal gammopathy of undetermined significance (MGUS) is common, but there are scarce data regarding the effect of DMARDs on this premalignant condition. We aimed to evaluate the impact of JAK inhibitors (JAKis) on MGUS when initiated for an active rheumatic disease. METHODS: Patients with monoclonal abnormality prior to JAKi initiation for an active rheumatic disease were identified through the MAJIK-SFR Registry, a French multicentre prospective study. Clinical and biological data were collected using a standardized case report form. RESULTS: Twenty patients were identified with a mean age of 65 years and a diagnosis of RA (n = 15), PsA (n = 3), and axial SpA (n = 2). The JAKi prescribed was baricitinib (n = 9), tofacitinib (n = 6) or upadacitinib (n = 5), with a mean duration of 15.5 months. Seventeen patients had individualized serum monoclonal protein (IgG kappa n = 9; IgG lambda n = 4; IgM kappa n = 3; IgA lambda n = 1) ranging from 0.16 to 2.3 g/dl, and three patients did not have an initial measurable spike but they had a positive serum immunofixation. With a follow-up of 4-28 months, the serum monoclonal protein level decreased in 8 of 17 patients (47%), remained stable in 8 patients (47%) and increased in 1 patient (6%). The maximal decrease observed was an initial IgG kappa of 2.3 g/dl, decreasing to 0.2 g/dl at month 14. CONCLUSION: This study provides reassuring and promising data on MGUS evolution in patients treated with JAKis for rheumatic diseases, which may guide the choice of treatment in patients with both conditions.


Assuntos
Artrite Psoriásica , Inibidores de Janus Quinases , Gamopatia Monoclonal de Significância Indeterminada , Doenças Reumáticas , Humanos , Idoso , Gamopatia Monoclonal de Significância Indeterminada/tratamento farmacológico , Inibidores de Janus Quinases/uso terapêutico , Estudos Prospectivos , Anticorpos Monoclonais , Doenças Reumáticas/tratamento farmacológico , Imunoglobulina G
3.
Rev Med Interne ; 41(9): 622-627, 2020 Sep.
Artigo em Francês | MEDLINE | ID: mdl-32660858

RESUMO

INTRODUCTION: Cocaine use is associated with multiple complications, some of which can mimic systemic diseases, especially Antineutrophil Cytoplasmic Antibody (ANCA) associated vasculitis. We report a case of Cocaine Induced Midline Destructive Lesions (CIMDL) for which a diagnosis of granulomatosis with polyangiitis (GPA) was discussed. CASE REPORT: A 42-year-old male, cocaine consumer, was admitted in our department for a centrofacial destructive process. He had no extra ear, nose and throat (ENT) involvement. ANCA were positive with a perinuclear fluorescence pattern and an anti-Proteinase 3 specificity. Regarding this unusual immunologic pattern and in the absence of histological argument for a GPA, a diagnosis of CIMDL was made. CONCLUSION: CIMDL is a centrofacial destructive process due to intranasal cocaine use. It is frequently associated with the presence of p-ANCA with both anti-HNE and anti-PR3 specificity.


Assuntos
Transtornos Relacionados ao Uso de Cocaína/complicações , Granulomatose com Poliangiite/etiologia , Perfuração do Septo Nasal/etiologia , Adulto , Anticorpos Anticitoplasma de Neutrófilos/efeitos adversos , Anticorpos Anticitoplasma de Neutrófilos/sangue , Transtornos Relacionados ao Uso de Cocaína/diagnóstico , Diagnóstico Diferencial , Granuloma Letal da Linha Média/diagnóstico , Granuloma Letal da Linha Média/etiologia , Granulomatose com Poliangiite/diagnóstico , Humanos , Masculino , Perfuração do Septo Nasal/diagnóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA